LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

LLY

1,017.74

+3%↑

JNJ

194.37

+0.29%↑

ABBV

233.26

+3.63%↑

UNH

339.07

+3.56%↑

AZN

87.67

-1.55%↓

Search

Revvity Inc

Geschlossen

BrancheGesundheitswesen

94.02 -0.3

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

93.48

Max

95.03

Schlüsselkennzahlen

By Trading Economics

Einkommen

-8.6M

47M

Verkäufe

-21M

699M

KGV

Branchendurchschnitt

47.567

105.69

EPS

0.4

Dividendenrendite

0.31

Gewinnspanne

6.675

Angestellte

11,000

EBITDA

-14M

181M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+17.8% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.31%

2.37%

Nächstes Ex-Dividendendatum

16. Jan. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-815M

10B

Vorheriger Eröffnungskurs

94.32

Vorheriger Schlusskurs

94.02

Nachrichtenstimmung

By Acuity

27%

73%

81 / 374 Ranking in Healthcare

Revvity Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Nov. 2025, 21:55 UTC

Ergebnisse

Xero Beats 1st Half Profit Expectations Despite Melio Margin Hit

12. Nov. 2025, 21:34 UTC

Ergebnisse

Cisco Systems Boosts Fiscal Year Outlook as 1Q Profit, Revenue Rise

12. Nov. 2025, 23:44 UTC

Market Talk

Nikkei May Trade in Range Amid Caution Over U.S. Econ -- Market Talk

12. Nov. 2025, 23:38 UTC

Market Talk

Gold Steady Ahead of Expected End to U.S. Government Shutdown -- Market Talk

12. Nov. 2025, 23:13 UTC

Ergebnisse

Samsung Fire & Marine Insurance 3Q Net Profit Largely Met FactSet-Compiled Consensus

12. Nov. 2025, 23:13 UTC

Ergebnisse

Samsung Fire & Marine Insurance 3Q Net KRW538.50B Vs. Net KRW554.56B >000810.SE

12. Nov. 2025, 23:13 UTC

Ergebnisse

Samsung Fire & Marine Insurance 3Q Oper Pft KRW664.06B Vs. Pft KRW717.46B >000810.SE

12. Nov. 2025, 23:13 UTC

Ergebnisse

Samsung Fire & Marine Insurance 3Q Rev KRW5.732T Vs. KRW5.326T >000810.SE

12. Nov. 2025, 22:30 UTC

Market Talk
Ergebnisse

Firefly Aerospace Sets Plan for Next Launch After Explosion -- Market Talk

12. Nov. 2025, 22:18 UTC

Ergebnisse

Cisco Systems Boosts Outlook on AI-Driven Demand -- Update

12. Nov. 2025, 22:12 UTC

Market Talk

Bank of Canada Rate Hikes Could Start in 2H 2026 -- Market Talk

12. Nov. 2025, 22:05 UTC

Ergebnisse

Pan American Silver: Campbell Succeeded Steve Busby >PAAS

12. Nov. 2025, 22:04 UTC

Ergebnisse

Pan American Silver Named Scott Campbell as Operating Chief on Oct. 20

12. Nov. 2025, 22:04 UTC

Ergebnisse

Pan American Silver 3Q Adj EPS 48c >PAAS

12. Nov. 2025, 22:04 UTC

Ergebnisse

Pan American Silver 3Q Rev $884.4M >PAAS

12. Nov. 2025, 22:04 UTC

Ergebnisse

Pan American Silver 3Q EPS 45c >PAAS

12. Nov. 2025, 22:03 UTC

Ergebnisse

Manulife Financial: 3Q Book Value Per Common Shr C$26.07 >MFC.T

12. Nov. 2025, 22:02 UTC

Ergebnisse

Manulife Financial 3Q Net C$1.8B >MFC

12. Nov. 2025, 22:02 UTC

Ergebnisse

Manulife Financial 3Q Adj EPS C$1.16 >MFC

12. Nov. 2025, 22:02 UTC

Ergebnisse

Manulife Financial 3Q EPS C$1.02 >MFC

12. Nov. 2025, 21:53 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope Steel: Sale Strengthens Focus on Own Growth Investments

12. Nov. 2025, 21:53 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope Steel Says Deal Subject to Indian Regulatory Approvals

12. Nov. 2025, 21:53 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope Steel Estimates Net Profit After Tax on Sale of A$70 Million

12. Nov. 2025, 21:53 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope Steel Expects Net Proceeds After Taxes, Fees of A$179 Million in 2H FY26

12. Nov. 2025, 21:52 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope Steel: Tata BlueScope Steel JV a Provider of Coated, Painted Steel Products in India

12. Nov. 2025, 21:51 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope Steel Agrees to Sell 50% Stake in Tata BlueScope Steel Joint Venture to Tata Steel

12. Nov. 2025, 21:50 UTC

Market Talk
Ergebnisse

Basic Materials Roundup: Market Talk

12. Nov. 2025, 21:49 UTC

Ergebnisse

Cisco Stock Climbs as Earnings Beat Expectations Amid Strong AI Demand -- Barrons.com

12. Nov. 2025, 21:48 UTC

Ergebnisse

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares. -- Barrons.com

12. Nov. 2025, 21:40 UTC

Ergebnisse

Xero Beats 1H Profit Expectations Despite Melio Margin Hit

Peer-Vergleich

Kursveränderung

Revvity Inc Prognose

Kursziel

By TipRanks

17.8% Vorteil

12-Monats-Prognose

Durchschnitt 111.1 USD  17.8%

Hoch 125 USD

Tief 100 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Revvity Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

11 ratings

8

Buy

3

Halten

0

Sell

Stimmung

By Acuity

81 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Revvity Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat